Business Description
Viridian Therapeutics Inc
NAICS : 325199
SIC : 2834
ISIN : US92790C1045
Total Employee Number:
252Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.04 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.37 | |||||
Debt-to-EBITDA | -0.66 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.66 | |||||
Beneish M-Score | 208.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 147.6 | |||||
3-Year EBITDA Growth Rate | 0.4 | |||||
3-Year EPS without NRI Growth Rate | -7 | |||||
3-Year FCF Growth Rate | -3.5 | |||||
3-Year Book Growth Rate | -1.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.87 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 138.23 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.28 | |||||
9-Day RSI | 74.79 | |||||
14-Day RSI | 70.81 | |||||
3-1 Month Momentum % | 22.7 | |||||
6-1 Month Momentum % | -31.35 | |||||
12-1 Month Momentum % | 26.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.95 | |||||
Quick Ratio | 16.95 | |||||
Cash Ratio | 15.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -35.1 | |||||
Shareholder Yield % | -21.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -569.68 | |||||
Net Margin % | -544.06 | |||||
EBITDA Margin % | -521.46 | |||||
FCF Margin % | -476.45 | |||||
OCF Margin % | -474.02 | |||||
ROE % | -63.68 | |||||
ROA % | -49.04 | |||||
ROIC % | -1157.82 | |||||
3-Year ROIIC % | -1407.97 | |||||
ROC (Joel Greenblatt) % | -9951.31 | |||||
ROCE % | -50.79 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 26.6 | |||||
PB Ratio | 4.42 | |||||
Price-to-Tangible-Book | 4.49 | |||||
EV-to-EBIT | -5.32 | |||||
EV-to-EBITDA | -5.33 | |||||
EV-to-Revenue | 27.77 | |||||
EV-to-Forward-Revenue | 152.49 | |||||
EV-to-FCF | -5.9 | |||||
Price-to-Median-PS-Value | 0.79 | |||||
| Price-to-Net-Current-Asset-Value | 4.54 | |||||
| Price-to-Net-Cash | 4.56 | |||||
Earnings Yield (Greenblatt) % | -18.8 | |||||
FCF Yield % | -12.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viridian Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 60.608 | ||
| EPS (TTM) (€) | -2.901 | ||
| Beta | 2.4411 | ||
| 3-Year Sharpe Ratio | 0.26 | ||
| 3-Year Sortino Ratio | 0.44 | ||
| Volatility % | 72.82 | ||
| 14-Day RSI | 70.81 | ||
| 14-Day ATR (€) | 0.812137 | ||
| 20-Day SMA (€) | 17.28 | ||
| 12-1 Month Momentum % | 26.23 | ||
| 52-Week Range (€) | 11.2 - 29.29 | ||
| Shares Outstanding (Mil) | 113.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viridian Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viridian Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 86 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 18.10 (+2.84%) | ||
| Lumvoaâ„¢ (veligrotug-vvze) FDA Approval | 2026-06-29 08:00 | 15.70 (+3.97%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 16:00 | 13.60 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 17:30 | 13.70 (-4.86%) | ||
| General meeting for 2026 | 2026-06-02 14:00 | 14.50 (-3.33%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 12.00 (+6.19%) | ||
| Guidance call for 2026 | 2026-03-09 08:00 | 24.36 (-0.77%) | ||
| Guidance call for 2026 | 2026-03-04 10:30 | 25.14 (-0.83%) | ||
| Annual report for 2025 | 2026-02-26 | 24.35 (-3.79%) |
Show
Entries
Viridian Therapeutics Inc Frequently Asked Questions
What is Viridian Therapeutics Inc(STU:1S1)'s stock price today?
The current price of STU:1S1 is €19.90. The 52 week high of STU:1S1 is €29.29 and 52 week low is €11.20.
When is next earnings date of Viridian Therapeutics Inc(STU:1S1)?
The next earnings date of Viridian Therapeutics Inc(STU:1S1) is 2026-11-05 Est..
Does Viridian Therapeutics Inc(STU:1S1) pay dividends? If so, how much?
Viridian Therapeutics Inc(STU:1S1) does not pay dividend.
Press Release
Articles on Viridian Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers